Overview

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals